Please assess the completion status of the following clinical trial:

Trial Title: Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained,~* Aged 18 or more,~* Pathologically proven stage IB, II or III NSCLC,~* Tumor expresses MAGE-A3,~* Free of distant metastasis,~* For Cohort 1, all of the following:~  1. Completely resected stage IB, II or IIIA NSCLC,~ 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard~ 3. ECOG performance status = 0 or 1~ 4. Due to receive adjuvant chemotherapy as permitted in the protocol~ 5. Not received, not receiving, and not due to receive adjuvant radiotherapy (except stage III patients)~ 6. First administration of chemotherapy can be scheduled within 4-12 weeks after surgery~* For Cohort 2, all of the following:~  1. Resected stage IB, II or IIIA NSCLC,~ 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard~ 3. ECOG PS = 0 or 1~ 4. Due to receive, or receiving, adjuvant chemotherapy as permitted in the protocol~ 5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (except stage III patients)~ 6. First administration of ASCI treatment can be scheduled within 2-4 weeks after the last administration of chemotherapy~ 7. Received at least 2 cycles of standard chemotherapy before ASCI treatment is initiated, whereafter no further chemotherapy is planned~* For Cohort 3, all of the following:~  1. Resected stage IB, II or IIIA NSCLC~ 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard~ 3. ECOG PS = 0 or 1 or 2~ 4. Not received, not receiving, and not due to receive, adjuvant chemotherapy~ 5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (this does not apply to patients in stage III)~ 6. First administration of ASCI treatment can be scheduled within 4-8 weeks after surgery~* For Cohort 4, all of the following:~  1. Unresectable stage III NSCLC~ 2. ECOG PS = 0 or 1 or 2~ 3. Due to receive, or receiving, chemo- and radiotherapy according to institution standard~ 4. Received at least 2 cycles of standard chemotherapy before the initiation of ASCI treatment, whereafter no further chemo-/radiotherapy is planned~ 5. Stable disease or objective response (confirmed by CT scan) after standard chemo-/radiotherapy~ 6. Administration of ASCI treatment can be scheduled within 2-6 weeks after the last administration of chemo-/radiotherapy~* Laboratory criteria: adequate bone-marrow reserve, adequate renal function, adequate hepatic function.~* For females: EITHER not of child-bearing potential, OR sexually abstinent, OR negative urine pregnancy test + use of adequate contraceptive precautions from 30 days before first study treatment till 2 months after completion of study treatment course~* In the view of the investigator, the patient can and will comply with the requirements of the protocol~Exclusion criteria:~* Previous or concomitant other malignancies, except if effectively treated and considered by the investigator highly likely to have been cured~* Pregnant or lactating~* History of anaphylaxis or severe allergic reaction~* Concurrent severe medical problems, unrelated to the malignancy, limiting full compliance with the study or exposing the patient to unacceptable risk~* Psychiatric or addictive disorders compromising the ability to give informed consent, or to comply with the trial procedures~* HIV-positive~* Require treatment with systemic corticosteroids, or other immunosuppressive agents~* Need home oxygenation~* Received or plan to receive investigational or non-registered product other than the study medication from 30 days before first dose of study medication and during whole study period~* History of chronic alcohol consumption and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
- Cohort 2 (Type: EXPERIMENTAL): Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
- Cohort 3 (Type: EXPERIMENTAL): Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
- Cohort 4 (Type: EXPERIMENTAL): Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.

Based on this trial design, predict the completion outcome and termination type (if applicable).